RestorGenex Corporation is a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology and dermatology. The Company's lead product is a PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The Company's pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. The Company's product candidates include RES-529, which is offered in the area of ophthalmology and oncology for Age-Related Macular Degeneration (AMD) and Glioblastoma Multiforme (GBM) conditions, respectively, and RES-440 for Acnes in the area of Dermatology. The Company has developed small molecule zinc-finger transcription factor inhibitors/activators.